MeiraGTx Holdings plc Q2 2024 10-Q Filing

TL;DR

MeiraGTx Q2 2024: $643.8M assets, $55.3M liabilities, $62.2M net loss. Still burning cash.

AI Summary

MeiraGTx Holdings plc filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $643.8 million and total liabilities of $55.3 million as of June 30, 2024. For the three months ended June 30, 2024, the company had a net loss of $62.2 million.

Why It Matters

This filing provides a financial snapshot of MeiraGTx Holdings plc, detailing their assets, liabilities, and net loss for the second quarter of 2024, which is crucial for investors to assess the company's financial health and performance.

Risk Assessment

Risk Level: medium — The company reported a significant net loss, indicating ongoing operational costs and potential financial strain.

Key Numbers

• $643.8B — Total Assets (As of June 30, 2024, indicating the company's total resources.)
• $55.3B — Total Liabilities (As of June 30, 2024, representing the company's total obligations.)
• $62.2B — Net Loss (Q2 2024) (For the three months ended June 30, 2024, showing the company's profitability.)

Key Players & Entities

• MeiraGTx Holdings plc (company) — Filer of the 10-Q
• 20240630 (date) — End of the reporting period
• 20240812 (date) — Filing date
• $643,763,960 (dollar_amount) — Total assets as of June 30, 2024
• $55,349,534 (dollar_amount) — Total liabilities as of June 30, 2024
• $62,221,145 (dollar_amount) — Net loss for the three months ended June 30, 2024

FAQ

Key Financial Figures

• $0.00003881 — on which registered Ordinary Shares, $0.00003881 par value per share MGTX The Nasdaq

Filing Documents

• mgtx-20240630x10q.htm (10-Q) — 2186KB
• mgtx-20240630xex10d1.htm (EX-10.1) — 18KB
• mgtx-20240630xex31d1.htm (EX-31.1) — 11KB
• mgtx-20240630xex31d2.htm (EX-31.2) — 11KB
• mgtx-20240630xex32d1.htm (EX-32.1) — 7KB
• mgtx-20240630xex32d2.htm (EX-32.2) — 7KB
• 0001558370-24-011788.txt ( ) — 8455KB
• mgtx-20240630.xsd (EX-101.SCH) — 57KB
• mgtx-20240630_cal.xml (EX-101.CAL) — 51KB
• mgtx-20240630_def.xml (EX-101.DEF) — 236KB
• mgtx-20240630_lab.xml (EX-101.LAB) — 433KB
• mgtx-20240630_pre.xml (EX-101.PRE) — 380KB
• mgtx-20240630x10q_htm.xml (XML) — 1418KB

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q (the "Form 10-Q") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 10-Q that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding expectations regarding meetings with global regulatory authorities and the FDA, product pipeline, anticipated product benefits, goals and strategic priorities, product candidate development and status and expectations relating to clinical trials, growth expectations or targets, pre-clinical and clinical data expectations and expectations related to financing arrangements and the intended use of proceeds thereunder, as well as statements that include the words "expect," "will," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "could," "should," "would," "continue," "anticipate" and similar statements of a future or forward-looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under "Item 1A. Risk Factors" in this Form 10-Q. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 10-Q. Any such forward-looking statements represent management's estimates as of the date of this Form 10-Q. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if s

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statement of Shareholders' Equity 3 Condensed Consolidated Statement of Shareholders' Equity 4 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 42 PART II. OTHER INFORMATION 43 Item 1.

Legal Proceedings

Legal Proceedings 43 Item 1A.

Risk Factors

Risk Factors 43 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 100 Item 3. Defaults Upon Senior Securities 100 Item 4. Mine Safety Disclosures 100 Item 5. Other Information 100 Item 6. Exhibits 101

Signatures

Signatures 102 iv Table of Contents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in thousands, except share and per share amounts) June 30, December 31, 2024 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 99,974 $ 129,566 Accounts receivable - related party 1,628 10,138 Prepaid expenses 4,955 5,625 Tax incentive receivable 3,557 13,277 Other current assets 660 1,016 Total Current Assets 110,774 159,622 Property, plant and equipment, net 108,844 115,896 Intangible assets, net 969 1,118 Restricted cash 1,051 1,083 Other assets 1,139 1,917 Equity method and other investments 6,766 6,766 Right-of-use assets - operating leases, net 13,823 15,910 Right-of-use assets - finance leases, net 23,285 24,432 TOTAL ASSETS $ 266,651 $ 326,744 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 21,398 $ 16,042 Accrued expenses 16,928 42,639 Lease obligations, current 4,212 4,193 Deferred revenue - related party, current 3,498 2,926 Other current liabilities 970 1,278 Total Current Liabilities 47,006 67,078 Deferred revenue - related party 53,763 34,017 Lease obligations 10,688 12,952 Asset retirement obligations 2,490 2,401 Note payable, net 72,665 72,119 TOTAL LIABILITIES 186,612 188,567 COMMITMENTS AND CONTINGENCIES (Note 11) SHAREHOLDERS' EQUITY: Ordinary Shares, $ 0.00003881 par value, 1,288,327,750 authorized, 64,684,187 and 63,601,015 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 3 2 Capital in excess of par value 706,943 693,841 Accumulated other comprehensive loss ( 3,614 ) ( 1,435 ) Accumulated deficit ( 623,293 ) ( 554,231 ) Total Shareholders' Equity 80,039 138,177 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 266,651 $ 326,744 See Notes to Condensed Consolidated Financial Statement

View Full Filing

View this 10-Q filing on SEC EDGAR